OSR Holdings Secures Nasdaq Extension to Pursue Major Licensing Deal and Regain Compliance

New York, Thursday, 5 March 2026.
OSR Holdings (NASDAQ:OSRH) has successfully obtained a 180-day extension from Nasdaq, setting a new compliance deadline of August 31, 2026. This strategic window allows the company to focus on a potentially transformative global licensing transaction for its subsidiary Vaximm AG. The proposed deal for the VXM01 asset is the centerpiece of their recovery strategy, featuring a structured payment plan that includes $30 million upfront and up to $815 million in milestone payments. Rather than opting for immediate, short-term fixes, management is utilizing this “operational runway” to consolidate its medical technology platforms and secure significant capital. This approach aims to organically drive the share price above the $1.00 minimum requirement through tangible value creation in immuno-oncology and regenerative biologics.